Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer

• Published in: International archives of medicine 2013-01, Vol.6 (1), p.2-2
• Main Authors: Moreno, Ricardo, Delgado, Pamela O, Coelho, Patrícia G, Marsicano, Sarah R, Boas, Viviane Av, Azzalis, Ligia A, Junqueira, Virgínia Bc, Rocha, Katya C, de Abreu, Luiz Carlos, Valenti, Vitor E, Drezzet, Jefferson, Pereira, Edimar Cristiano, Fonseca, Fernando L
• Format: Article
• Language: English
• Subjects: Short Report
• ISSN: 1755-7682; 1755-7682
• DOI: 10.1186/1755-7682-6-2

Several studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (Nanovue™-NV) in samples of 80 patients with prostate cancer. Blood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation. There was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 μg/mL. Average variation between 51 samples was 10.29 μg/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology. Determination of plasma DNA by nanotechnology was not reproducible.